Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:

NCT ID: NCT05372874 Not yet recruiting - Hepatitis C Clinical Trials

Treatment of Hepatitis c by Using Direct-acting Antiviral

Start date: May 6, 2022
Phase:
Study type: Observational

Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression. Chronic stress shunt tryptophan which is essential amino acid toward kynurenic pathway leading to lower level of serotonin and melatonin level. Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV).

NCT ID: NCT05276700 Not yet recruiting - HCV Clinical Trials

Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection

Start date: July 15, 2022
Phase:
Study type: Observational

find the role of alpha one microglobulin (as an early renal tubular biomarker) to identify and evaluate the prevalence of early renal manifestations among patients with chronic HCV and compared these patients with HCV-negative healthy individuals

NCT ID: NCT05102838 Not yet recruiting - Hepatitis C Clinical Trials

Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C

Start date: November 1, 2021
Phase:
Study type: Observational

Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030. However, at present, the diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face. This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.

NCT ID: NCT05071261 Not yet recruiting - Clinical trials for Hepatitis C Virus Infection

Screening, Treatment, and Eradication of Hep C

Start date: April 1, 2024
Phase:
Study type: Observational

The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and flyers.

NCT ID: NCT04690972 Not yet recruiting - Liver Cancer Clinical Trials

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".

LivMOD
Start date: December 20, 2020
Phase:
Study type: Observational

Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.

NCT ID: NCT04618679 Not yet recruiting - Hepatitis C Clinical Trials

Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.

Start date: November 2, 2020
Phase:
Study type: Observational

-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.

NCT ID: NCT04543643 Not yet recruiting - Clinical trials for Gastroesophageal Varices

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

CABER
Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study, we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by observing the changes of endoscopy,endoscopic ultrasonography and intestinal flora.

NCT ID: NCT04470271 Not yet recruiting - Viral Hepatitis C Clinical Trials

Re-linkage to Care of Patients With Hepatitis C

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care

NCT ID: NCT04428346 Not yet recruiting - Clinical trials for Hepatitis C, Chronic

A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

AMPLIFY
Start date: October 2022
Phase: N/A
Study type: Interventional

A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study

NCT ID: NCT04244383 Not yet recruiting - Hepatitis C Clinical Trials

Expression of Inflammasomes in HCV Patients

Inflammasome
Start date: January 2020
Phase: Phase 4
Study type: Interventional

Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously during acute infection. Elimination of HCV during acute infection correlates with a rapid induction of innate and a delayed induction of adaptive immune responses. The majority of patients is unable to clear the virus and develops viral persistence despite the ongoing innate and adaptive immune response. The virus usually develops several strategies to escape these immune responses.